Labeled nucleotide analogs, reaction mixtures, and methods and systems for sequencing
US-12000000-B2 · Jun 4, 2024 · US
US2025002989A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2025002989-A1 |
| Application number | US-202418675708-A |
| Country | US |
| Kind code | A1 |
| Filing date | May 28, 2024 |
| Priority date | Nov 20, 2015 |
| Publication date | Jan 2, 2025 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Labeled nucleotide analogs comprising at least one avidin protein, at least one dye-labeled compound, and at least one nucleotide compound are provided. The analogs are useful in various fluorescence-based analytical methods, including the analysis of highly multiplexed optical reactions in large numbers at high densities, such as single molecule real time nucleic acid sequencing reactions. The analogs are detectable with high sensitivity at desirable wavelengths. They contain structural components that modulate the interactions of the analogs with DNA polymerase, thus decreasing photodamage and improving the kinetic and other properties of the analogs in sequencing reactions. Also provided are nucleotide and dye-labeled compounds of the subject analogs, as well as intermediates useful in the preparation of the compounds and analogs. Compositions comprising the compounds, methods of synthesis of the intermediates, compounds, and analogs, and mutant DNA polymerases are also provided.
Opening claim text (preview).
1 - 80 . (canceled) 81 . A labeled nucleotide analog comprising: a first avidin protein having four subunits, each subunit comprising one biotin binding site; a first nucleotide compound bound to the first avidin protein, the first nucleotide compound comprising a polyphosphate element, a nucleoside element, an optional multivalent central core element, a terminal coupling element, and a nucleotide linker element, wherein the first nucleotide compound comprises at least one affinity modulating element; and a first dye-labeled compound bound to the first avidin protein, wherein the first dye-labeled compound is a compound of structural formula (IIIA), (IIIB), (IIIC), (IIID), or (IIIE): wherein each L′ is independently a dye compound linker element; each S is independently a shield element; each A is independently an acceptor dye; each D is independently a donor dye; each B″ is independently a terminal coupling element; each p is independently 0 or 1; and each r is independently an integer from 0 to 8; wherein the compound comprises at least one shield element, at least one acceptor dye, and at least one donor dye. 82 . The labeled nucleotide analog of claim 81 , wherein each r is independently an integer from 0 to 4. 83 . The labeled nucleotide analog of claim 81 , wherein the first dye-labeled compound comprises at least two donor dyes. 84 . (canceled) 85 . The labeled nucleotide analog of claim 81 , wherein the first dye-labeled compound comprises at least two acceptor dyes. 86 . (canceled) 87 . The labeled nucleotide analog of claim 81 , wherein the first dye-labeled compound comprises at least two donor dyes and at least two acceptor dyes. 88 . The labeled nucleotide analog of claim 81 , wherein at least one dye compound linker element comprises a shield element or a side chain element. 89 - 101 . (canceled) 102 . The labeled nucleotide analog of claim 81 comprising two terminal coupling elements. 103 . The labeled nucleotide analog of claim 81 , wherein the terminal coupling element comprises a biotin moiety. 104 . The labeled nucleotide analog of claim 103 , wherein the terminal coupling element comprises a bis-biotin moiety. 105 . The labeled nucleotide analog of claim 81 , wherein the at least one acceptor dye or the at least one donor dye is a cyanine dye. 106 . The labeled nucleotide analog of claim 81 , wherein the first dye-labeled compound does not contain a nucleoside. 107 . A labeled nucleotide analog comprising: a first avidin protein having four subunits, each subunit comprising one biotin binding site; a first nucleotide compound bound to the first avidin protein, the first nucleotide compound comprising a polyphosphate element, a nucleoside element, an optional multivalent central core element, a terminal coupling element, and a nucleotide linker element, wherein the first nucleotide compound comprises at least one affinity modulating element; and a first dye-labeled compound bound to the first avidin protein, wherein the first dye-labeled compound is a compound of structural formula (IIF): wherein each L′ is independently a dye compound linker element; each S is independently a shield element; each A is independently an acceptor dye; each D is independently a donor dye; each B″ is independently a terminal coupling element; each p is independently 0 or 1; and each r′ is independently an integer from 0 to 4; wherein the compound comprises at least one shield element, at least one acceptor dye, and at least one donor dye. 108 . The labeled nucleotide analog of claim 107 , wherein each r′ is independently an integer from 0 to 2. 109 . The labeled nucleotide analog of claim 108 , wherein each r′ is independently 0 or 1. 110 . The labeled nucleotide analog of claim 107 comprising at least two donor dyes. 111 . (canceled) 112 . The labeled nucleotide analog of claim 107 comprising at least two acceptor dyes. 113 . (canceled) 114 . The labeled nucleotide analog of claim 107 comprising at least two donor dyes and at least two acceptor dyes. 115 . The labeled nucleotide analog of claim 107 , wherein at least one dye compound linker element comprises a shield element or a side chain element. 116 - 128 . (canceled) 129 . The labeled nucleotide analog of claim 107 comprising two terminal coupling elements. 130 . The labeled nucleotide analog of claim 107 , wherein the terminal coupling element comprises a biotin moiety. 131 . The labeled nucleotide analog of claim 130 , wherein the terminal coupling element comprises a bis-biotin moiety. 132 . The labeled nucleotide analog of claim 107 , wherein the at least one acceptor dye or the at least one donor dye is a cyanine dye. 133 . The labeled nucleotide analog of claim 107 , wherein the first one dye-labeled compound does not contain a nucleoside. 134 - 187 . (canceled)
Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes} · CPC title
containing a methine or polymethine dye · CPC title
the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide · CPC title
with the saccharide radical esterified by phosphoric or polyphosphoric acids · CPC title
Methods for sequencing · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.